Sign up to receive our twice-weekly e-Newsletter
HIV
and
Hepatitis
.com
Elvitegravir
(GS-9137)
GS-9160 and GS-9350 and GS-9148
Gilead Releases 24 Week Data on "Quad" Pill containing
Elvitegravir
and Experimental Boosting Agent GS 9350
1/08/10
Investigational Pharmaco-enhancer
GS-9350
Equals Ritonavir (Norvir) as a Booster for Atazanavir (Reyataz)
9/25/09
Discovery of
GS-9350
: A Novel Pharmacoenhancer without Anti-HIV Activity
9/12/09
Pharmacokinetic Boosting of Atazanavir with the Pharmacoenhancer
GS-9350
versus Ritonavir
2/21/09
Viral Resistance to the HIV-1 Integrase Inhibitor
GS-9160
2/10/09
GS-9350
: A Pharmacoenhancer Without Anti-HIV Activity
2/10/09
High Resolution Crystallographic Analysis of the Competitive Binding of a Novel Nucleotide Analog
GS-9148-Diphosphate
to HIV-1 Reverse TranscriptaseEB
- 2/10/09
Gilead Plans Clinical Trial of 4-in-1 Antiretroviral Combination Pill Containing Experimental Integrase Inhibitor
Elvitegravir
- 1/20/09
Gilead Announces Start of Phase III Efficacy Trial of Experimental
Integrase Inhibitor Elvitegravir
in Treatment-experienced HIV Patients
7/25/08
FDA-approved HIV
and AIDS Treatments
Protease Inhibitors
PIs
non Nucleoside Reverse
Transcriptase Inhibitors
nNRTIs
Nucleoside / Nucleotide
Reverse Transcriptase Inhibitors
NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors
EIs
Integrase Inhibitors
Experimental Treatments
HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines
Women/Children
